MX2021013489A - Combinacion farmaceutica que comprende trazodona para el tratamiento del dolor neuropatico. - Google Patents

Combinacion farmaceutica que comprende trazodona para el tratamiento del dolor neuropatico.

Info

Publication number
MX2021013489A
MX2021013489A MX2021013489A MX2021013489A MX2021013489A MX 2021013489 A MX2021013489 A MX 2021013489A MX 2021013489 A MX2021013489 A MX 2021013489A MX 2021013489 A MX2021013489 A MX 2021013489A MX 2021013489 A MX2021013489 A MX 2021013489A
Authority
MX
Mexico
Prior art keywords
trazodone
treatment
neuropathic pain
pharmaceutical combination
mirogabalin
Prior art date
Application number
MX2021013489A
Other languages
English (en)
Inventor
Serena Tongiani
Fabrizio Calisti
Lorenzo Polenzani
Paola Lipone
Original Assignee
Acraf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=67875917&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2021013489(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Acraf filed Critical Acraf
Publication of MX2021013489A publication Critical patent/MX2021013489A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se relaciona a una composición farmacéutica la cual comprende (a) una combinación de (i) trazodona o una sal de la misma, y (ii) gabapentina o pregabalina o mirogabalina o una sal de las mismas o un profármaco de las mismas, y (b) por lo menos un excipiente aceptable farmacéuticamente, para uso en el tratamiento de dolor neuropático, en donde la composición farmacéutica comprende una proporción en peso de trazodona: gabapentina o pregabalina o mirogabalina entre 1:40 y 1:100, preferentemente menor a 1:40 y hasta 1:100.
MX2021013489A 2019-05-07 2020-05-06 Combinacion farmaceutica que comprende trazodona para el tratamiento del dolor neuropatico. MX2021013489A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT102019000006602A IT201900006602A1 (it) 2019-05-07 2019-05-07 Composizione farmaceutica per il trattamento del dolore neuropatico
PCT/IB2020/054275 WO2020225740A1 (en) 2019-05-07 2020-05-06 Pharmaceutical combination comprising trazodone for the treatment of neuropathic pain

Publications (1)

Publication Number Publication Date
MX2021013489A true MX2021013489A (es) 2021-12-10

Family

ID=67875917

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021013489A MX2021013489A (es) 2019-05-07 2020-05-06 Combinacion farmaceutica que comprende trazodona para el tratamiento del dolor neuropatico.

Country Status (26)

Country Link
US (1) US20220211699A1 (es)
EP (1) EP3965752B1 (es)
JP (1) JP2022532518A (es)
KR (1) KR20220006049A (es)
CN (1) CN113825505A (es)
AU (1) AU2020267954A1 (es)
BR (1) BR112021021410A2 (es)
CA (1) CA3135097A1 (es)
DK (1) DK3965752T3 (es)
EA (1) EA202193050A1 (es)
ES (1) ES2962966T3 (es)
FI (1) FI3965752T3 (es)
GE (1) GEP20237524B (es)
HR (1) HRP20231252T1 (es)
HU (1) HUE063756T2 (es)
IL (1) IL287529B (es)
IT (1) IT201900006602A1 (es)
LT (1) LT3965752T (es)
MX (1) MX2021013489A (es)
PL (1) PL3965752T3 (es)
PT (1) PT3965752T (es)
RS (1) RS64783B1 (es)
SG (1) SG11202110709QA (es)
SI (1) SI3965752T1 (es)
UA (1) UA128174C2 (es)
WO (1) WO2020225740A1 (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1849153A (zh) 2003-09-12 2006-10-18 辉瑞大药厂 含有α－2－δ配体和5－羟色胺/去甲肾上腺素重摄取抑制剂的组合物
WO2006069293A2 (en) * 2004-12-22 2006-06-29 Friedman Robert S Composition comprising n-acetylcysteine and further pain or anti- inflamm medications
US20120083508A1 (en) * 2006-12-22 2012-04-05 Allergan, Inc. Alpha-2b receptor agonist and anticonvulsant compositions for treating chronic pain
WO2009021058A2 (en) * 2007-08-06 2009-02-12 Trinity Labortories, Inc. Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy
KR20130002292A (ko) 2011-06-28 2013-01-07 주식회사 비보존 다중 타겟팅의 상승 효과를 유발하는 유효물질의 조합 및 그 용도
JP6924184B2 (ja) 2015-10-22 2021-08-25 アジェンデ・キミケ・リウニテ・アンジェリニ・フランチェスコ・ア・チ・エレ・ア・エフェ・ソシエタ・ペル・アチオニＡｚｉｅｎｄｅ Ｃｈｉｍｉｃｈｅ Ｒｉｕｎｉｔｅ Ａｎｇｅｌｉｎｉ Ｆｒａｎｃｅｓｃｏ Ａ．Ｃ．Ｒ．Ａ．Ｆ．Ｓｏｃｉｅｔａ Ｐｅｒ Ａｚｉｏｎｉ 疼痛の治療のための医薬組成物

Also Published As

Publication number Publication date
EP3965752A1 (en) 2022-03-16
IL287529A (en) 2021-12-01
JP2022532518A (ja) 2022-07-15
DK3965752T3 (da) 2023-10-09
CA3135097A1 (en) 2020-11-12
LT3965752T (lt) 2023-11-10
AU2020267954A1 (en) 2021-10-28
ES2962966T3 (es) 2024-03-22
HUE063756T2 (hu) 2024-01-28
IT201900006602A1 (it) 2020-11-07
UA128174C2 (uk) 2024-04-24
PL3965752T3 (pl) 2024-01-29
SI3965752T1 (sl) 2023-12-29
IL287529B (en) 2022-05-01
US20220211699A1 (en) 2022-07-07
GEP20237524B (en) 2023-08-10
PT3965752T (pt) 2023-10-02
EP3965752B1 (en) 2023-08-30
RS64783B1 (sr) 2023-11-30
EA202193050A1 (ru) 2022-02-10
FI3965752T3 (fi) 2023-10-04
SG11202110709QA (en) 2021-11-29
HRP20231252T1 (hr) 2024-02-02
CN113825505A (zh) 2021-12-21
WO2020225740A1 (en) 2020-11-12
BR112021021410A2 (pt) 2021-12-21
KR20220006049A (ko) 2022-01-14

Similar Documents

Publication Publication Date Title
MX2021004431A (es) Procesos novedosos.
MX2022014313A (es) Formulaciones para administracion oral de agentes activos con perfil de absorcion controlada.
MX2019012884A (es) Terapia de combinacion.
MX2018003331A (es) Administracion de potenciadores de regulador de la conductancia transmembrana de fibrosis quistica (cftr) deuterados.
EA201691454A1 (ru) Композиции придопидина модифицированного высвобождения
MX2022002196A (es) Composición de liberación retardada de niclosamida y uso antiviral de la misma.
MX2020010300A (es) Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas.
MX2023014492A (es) Compuestos utiles en la terapia para el vih.
PH12020551118A1 (en) Modified lipidated relaxin b chain peptides and their therapeutic use
MX2021005967A (es) Formas purificadas de rofecoxib, métodos de fabricación y uso.
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
PH12019500618A1 (en) Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease
JOP20210230A1 (ar) صياغات صيدلانية
MX2022000143A (es) Metodos novedosos.
MX2020008063A (es) Nuevos usos.
MX370065B (es) Acido (2r,4r)-5-(5'-cloro-2'-fluorobifenil-4-il)-2-hidroxi-4-[(5-m etiloxazol-2-carbonil)amino]pentanoico.
PH12019502510A1 (en) Pharmaceutical composition and pharmaceutical dosage form comprising (e)-4-(2-(aminomethyl)-3-fluoroallyloxy)-n-tert-butylbenzamide, process for their preparation, methods for treating and uses thereof
MX2021011986A (es) Metodos de tratamiento de dolor neuropatico.
PH12020500204A1 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic disease
MX2021013489A (es) Combinacion farmaceutica que comprende trazodona para el tratamiento del dolor neuropatico.
WO2016163818A3 (ko) 2-메톡시-4-(3-(4-메톡시페닐)프로필-1-엔-1-일)페놀을 유효성분으로 함유하는 염증성 질환 또는 관절염 치료 또는 예방용 약학적 조성물
WO2019241306A3 (en) Combination therapy with neoantigen vaccine
PH12020551620A1 (en) Compositions for preventing or treating dry eye
MX2021007324A (es) Terapia oral con acido 6,8-bis-benciltio-octanoico.
PH12020500001A1 (en) Non-pulsatile prolonged-release betahistine oral solid compositions